London, United Kingdom — As weight-loss medications gain popularity, two women are navigating the complex journey of losing weight and managing the implications of stopping treatment. Both successful in shedding significant pounds through the use of GLP-1 medications, Ellen and Tanya now grapple with the daunting question of what happens when they stop taking the drugs.

Tanya Hall, a sales manager, began using Wegovy, a popular GLP-1 drug, after feeling that her weight prevented her from being taken seriously in her professional life. Initially, the medication provided relief from the constant urge to eat, allowing her to lose about 38 kilograms (84 pounds). However, she quickly learned that the side effects—ranging from headaches to rapid hair loss—compounded her challenges. Despite eight months of success, she struggled with the anxiety that accompanied attempts to stop the medication. Each time she tried, strong cravings returned almost immediately, leaving her feeling overwhelmed and regretful.

Dr. Hussain Al-Zubaidi, a lifestyle GP, emphasizes that halting weight-loss drugs can feel like “jumping off a cliff.” He reports that many patients who discontinue medication often find themselves rapidly regaining the weight they lost. Research indicates that within one to three years of stopping treatment, an alarming percentage—between 60% and 80%—of lost weight often returns. This “food noise,” or the incessant urge to eat, can return almost instantly, complicating the path to sustained weight management.

In contrast, Ellen Ogley found her experience with the weight-loss medication Mounjaro transformative in more ways than one. After reaching a critical point in her health, she decided to try the injection as her last hope for substantial change. Her relationship with food shifted significantly while on the medication. Where emotional binge eating once plagued her, she discovered healthier coping mechanisms—exercise became her go-to instead of comfort eating. After 16 weeks, Ellen lost 22 kilograms (49 pounds) before tapering off the drug. Unlike Tanya, she has been able to maintain her weight loss, attributing her success to newfound knowledge about nutrition and a supportive environment.

Both women’s experiences underscore the essential role of ongoing support and strategy when transitioning off these medications. Dr. Al-Zubaidi advocates for comprehensive support systems for patients, particularly emphasizing the importance of guidance from healthcare providers to navigate the challenges that arise once medication stops.

Ellen’s remarkable eight-stone (51 kilograms) weight loss represents not just a physical transformation but a psychological one as well. She encourages others to know that sustainable life changes are achievable without medication. Tanya, now feeling comfortable at her lower weight, faces a different reality. She acknowledges a reliance on the medication to maintain her progress and grapples with the notion that quitting might lead her down an unwanted path.

The pharmaceutical companies behind these medications, like Eli Lilly for Mounjaro and Novo Nordisk for Wegovy, assert their commitment to patient safety and effective monitoring of their products. As the landscape of weight management continues to evolve, both medical professionals and patients alike are left to ponder: How can one successfully navigate life after weight-loss drugs? Through insight, dialogue, and support, clinicians and patients hope to understand and implement strategies that foster success beyond the medication.

While weight-loss drugs present a promising avenue for many, the complex interplay of biology, psychology, and social factors highlights the ongoing challenge of maintaining weight loss in a society increasingly wrestling with obesity. The stories of Ellen and Tanya illuminate this crucial discourse, emphasizing the need for a balanced approach to long-term health and well-being.